Nanogen, Inc. (NASDAQ: NGEN) is a diagnostics company engaging in the development, manufacturing, and selling of medical products for use in the in vitro diagnostics market in the United States, Canada, and Europe. The company’s advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. Since their inception into the diagnostics market, they have established themselves as a leader in nanotechnology which possesses the promise of miniaturization as they continue to be supported for their potential for diagnostic and bio-defense applications.
The company’s products help physicians to deliver enhanced patient care, allowing for faster and easier diagnoses and treatment and monitoring of cardiovascular and infectious disease. Their solutions are sent to clinical labs for research, allowing them to offer quality and cost-effective reagents and instruments for diagnostic and screening tests. Nanogen has continued to seek and develop innovative products that will revolutionize the bio-medical and healthcare markets. Their products span a wide range of applications for customers including: probes and primers for the molecular biology researcher, instrumentation for the clinical laboratory, reagents for multiplexed molecular targets, and rapid diagnostic tests.
The NanoChip® is the company’s second-generation automated multiplexing platform, which uses advanced microarray technology for performing pathogen sequence detection and genotyping applications. At the core of the NanoChip® is the NanoChip cartridge that provides multi-sampling and multi-targeted reporting capabilities. As the NanoChip arrays are built by users rather than containing pre-determined content, the system provides a simple, fast and cost effective means for performing molecular testing.
The company has also developed a proprietary MGB moiety that provides optimal performance for DNA probe-target hybridization reactions. The product is applied to the end of a DNA probe during synthesis on a commercial synthesizer, allowing the MGM moiety to fold back into the mirror groove formed by the DNA duplex to stabilize hybridization. This results in an increase in melting temperature, and the MGB moiety produces a “TM leveling” effect as A-T content increases. Since there is a rise in melting temperature due to the MGB moiety, physicians can utilize a shorter probe with improved mismatch discrimination.
Let us hear your thoughts: Nanogen, Inc. Message Board
